Recite me link

Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:
a. Afatinib
b. Alectinib
c. Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel
d. Atezolizumab monotherapy
e. Bevacizumab
f. Brigatinib
g. Ceritinib
h. Crizotinib
i. Dacomitinib
j. Docetaxel monotherapy
k. Durvalumab
l. Erlotinib
m. Gefitinib
n. Gemcitabine
o. Necitumumab
p. Nintedanib with Docetaxel
q. Nivolumab
r. Osimertinib
s. Paclitaxel
t. Pembrolizumab chemo in combination
u. Pembrolizumab monotherapy
v. Pemetrexed
w. Pemetrexed with Carboplatin
x. Pemetrexed with Cisplatin
y. Ramucirumab
z. Vinorelbine and cisplatin/carboplatin
Q2. Could you please provide the total number of patients with any treatment in the last three months for:
a. Total non-small cell lung cancer (NSCLC)
b. Squamous non-small cell lung cancer (Sq NSCLC)
c. Non-squamous non-small cell lung cancer (Non-Sq NSCLC)

Download response Incidence and treatment of Lung cancer. 091020